$BOLDBoundless Bio, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• ‘It’s actually very radical’: NIH debuts tool to help scientists navigate biomedical database
  The NIH’s National Library of Medicine has released the pilot version of a new tool designed to help scientists plumbing the library’s digital trove of scientific papers find related research faster.
  fiercebiotech · 13d ago
• Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
  With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a…
  fiercebiotech · 14d ago
• ARPA-H launches SPECTRA program, new autism research initiative
  Researchers will create an end-to-end system to identify ASD risk factors, connect patients to appropriate interventions and accelerate clinical research for new therapies.
  fiercebiotech · 17d ago
• After Novartis’ devastating M&A losses, long live the executive willing to try
  Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
  biospace · 17d ago
• Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol
  A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can quickly sober up people who have had too much to drink.
  fiercebiotech · 17d ago
• Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
  Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fi…
  fiercebiotech · 1mo ago
• RevMed could become ‘next oncology titan’ with Rasonque nod
  A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.
  biospace · 1mo ago
• Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
  Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.
  fiercebiotech · 1mo ago
• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 1mo ago
• Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
  Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
  fiercebiotech · 2mo ago